A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 696 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma MOST POPULAR First treatment approved in England for advanced bile duct cancer July 22, 2021 Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective May 10, 2022 Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... January 7, 2021 How we are working with industry to translate research into real... April 26, 2022 Load more HOT NEWS Working to Address Inequities in Cancer Care: 2021 ASCO Annual Meeting... FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy
